Date Added: 19/09/2017

Date Updated: 19/09/2017

Injectable extended-release naltrexone to treat opioid use disorder

Specialties: Anaesthetics, pain relief, ITU - Mental health, addiction & learning difficulties

Technology Type: Drugs

Stage of development: Established

Stage of EAA: Assessment Complete

Description, patients and keywords:

Vivitrol is an extended-release injectable formulation of naltrexone, administered as an intramuscular injection once a month. Naltrexone is an opioid-receptor antagonist that blocks the euphoric effects of opioids. Unlike other treatments for opioid use disorder, including buprenorphine/naloxone and methadone, naltrexone is not associated with the development of tolerance and dependence, and lacks the potential for misuse and diversion. However, because the oral formulation requires a daily dosage, poor adherence to the medication has limited its efficacy for the prevention of relapse in patients with opioid use disorder. The extended-release injectable formulation of naltrexone was developed to improve treatment adherence and retention.

Keywords: opioid addiction, drug abuse, Naltrexone, Vivitrol, opioid-receptor antagonists